Holen Sie sich die Stockscreener-App
133.02
0.54%
-0.72
Handel nachbörslich:
133.30
0.28
+0.21%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$133.74
Offen:
$134.085
24-Stunden-Volumen:
4.82M
Relative Volume:
0.78
Marktkapitalisierung:
$231.52B
Einnahmen:
$43.11B
Nettoeinkommen (Verlust:
$13.94B
KGV:
16.64
EPS:
7.9963
Netto-Cashflow:
$6.78B
1W Leistung:
-0.69%
1M Leistung:
+0.06%
6M Leistung:
+6.54%
1J Leistung:
+17.34%
1-Tages-Spanne:
$131.93
$134.09
1-Wochen-Bereich:
$129.08
$135.45
52-Wochen-Spanne:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Firmenname
Abbott Laboratories
Sektor
Branche
Telefon
(224) 667-6100
Adresse
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Vergleichen Sie ABT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-18 | Hochstufung | Jefferies | Hold → Buy |
| 2025-06-16 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-10-08 | Eingeleitet | Oppenheimer | Outperform |
| 2024-09-19 | Eingeleitet | Piper Sandler | Overweight |
| 2024-07-30 | Herabstufung | Edward Jones | Buy → Hold |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-21 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | Bestätigt | Barclays | Overweight |
| 2023-04-20 | Bestätigt | Bernstein | Outperform |
| 2023-04-20 | Bestätigt | JP Morgan | Overweight |
| 2023-04-20 | Bestätigt | Raymond James | Outperform |
| 2023-04-20 | Bestätigt | UBS | Buy |
| 2023-04-20 | Bestätigt | Wolfe Research | Underperform |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2022-10-26 | Eingeleitet | Mizuho | Neutral |
| 2022-10-18 | Eingeleitet | Barclays | Overweight |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-07-06 | Eingeleitet | Wolfe Research | Underperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-01-27 | Bestätigt | Credit Suisse | Outperform |
| 2022-01-27 | Bestätigt | Morgan Stanley | Overweight |
| 2022-01-27 | Bestätigt | Raymond James | Outperform |
| 2022-01-27 | Bestätigt | UBS | Buy |
| 2021-12-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-10-27 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | Eingeleitet | Redburn | Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Neutral |
| 2021-01-28 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-09-11 | Eingeleitet | Wolfe Research | Outperform |
| 2020-06-01 | Herabstufung | Goldman | Neutral → Sell |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2020-02-13 | Eingeleitet | Goldman | Neutral |
| 2020-02-06 | Fortgesetzt | BTIG Research | Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-06-13 | Bestätigt | BofA/Merrill | Buy |
| 2019-02-07 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-02 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-11-30 | Hochstufung | Goldman | Neutral → Buy |
| 2018-10-16 | Eingeleitet | Barclays | Overweight |
| 2018-06-27 | Eingeleitet | Bernstein | Outperform |
| 2018-01-30 | Bestätigt | Citigroup | Neutral |
| 2018-01-25 | Bestätigt | Stifel | Buy |
| 2018-01-25 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2018-01-02 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-10-19 | Bestätigt | Stifel | Buy |
Alle ansehen
Abbott Laboratories Aktie (ABT) Neueste Nachrichten
Evercore ISI Adjusts Abbott Laboratories Price Target to $144 From $140, Maintains Outperform Rating - MarketScreener
Abbott Laboratories' (NYSE:ABT) Returns On Capital Are Heading Higher - Yahoo
The Zacks Analyst Blog Highlights Advanced Micro Devices, Abbott Laboratories and Micron Technology - Zacks Investment Research
Thyroid Cancer Diagnostics Market Size to Surge USD 5.22 Billion at 5.34% CAGR by 2034 - GlobeNewswire Inc.
Precision Trading with Abbott Laboratories (ABT) Risk Zones - news.stocktradersdaily.com
Is Abbott Laboratories (ABL) stock positioned for secular growthPortfolio Update Summary & Low Drawdown Trading Strategies - newser.com
What candlestick patterns are forming on Abbott LaboratoriesMarket Risk Analysis & Risk Controlled Swing Alerts - newser.com
Top Stock Reports for AMD, Abbott & Micron Technology - The Globe and Mail
Abbott (ABT) Laps the Stock Market: Here's Why - Yahoo Finance
How Abbott Laboratories (ABT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Abbott Laboratories (ABT): Exploring Valuation as Steady Gains Draw Investor Interest in 2024 - simplywall.st
Abbott (ABT) Is Considered a Good Investment by Brokers: Is That True? - Yahoo
‘Few missions more meaningful than improving global health,’ says HR expert - Silicon Republic
Why analysts recommend Abbott Laboratories (ABL) stockJuly 2025 Breakouts & Long-Term Safe Investment Ideas - newser.com
Ready To Pass On Abbott Laboratories (NYSE:ABT)? Think Again - 富途牛牛
Goldman Sachs Maintains Abbott Laboratories(ABT.US) With Buy Rating - 富途牛牛
Abbott Laboratories (ABT) Maintains Strong MedTech Growth Outlook - Insider Monkey
2 Profitable Stocks to Consider Right Now and 1 We Find Risky - FinancialContent
Abbott Laboratories Q3 Earnings Preview: Profit boost expected - MSN
Abbott Gains Diabetes Tech Expansion Opportunity Following Earnings Beat and Insider Sale - MSN
Europe Clinical Nutrition Market to hit US$ 36.63 Billion by 2033 - openPR.com
Will Abbott Laboratories (Common Stock) (ABL0) stock attract long term capital inflowsJuly 2025 PreEarnings & Low Risk High Reward Ideas - newser.com
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $157 From $153, Maintains Buy Rating - MarketScreener
Abbott (ABT) Gains Attention with Inclusion in Goldman Sachs Con - GuruFocus
Will Abbott Laboratories (ABL) stock return to pre crash levelsJuly 2025 Highlights & Consistent Growth Stock Picks - newser.com
Abbott wins Health Canada approval for Esprit drug-eluting, dissolving scaffold - MassDevice
Union Bancaire Privee UBP SA Sells 30,201 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT is Paradiem LLC's 5th Largest Position - MarketBeat
Synlait to sell North Island assets to Abbott for $178m - FoodBev Media
Health Canada authorises Abbott’s Esprit BTK system for CLTI treatment - Medical Device Network
HB Wealth Management LLC Cuts Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Janney Montgomery Scott LLC - MarketBeat
How buyback programs support Abbott Laboratories stockMarket Risk Summary & Long-Term Capital Growth Ideas - newser.com
How Abbott Laboratories stock responds to policy changesJuly 2025 Market Mood & High Yield Stock Recommendations - newser.com
Synlait Milk agrees North Island asset sale to Abbott Laboratories - Global Food Industry News
Strategies to average down on Abbott LaboratoriesRecession Risk & AI Based Buy and Sell Signals - newser.com
Abbott Laboratories (ABT): A Healthcare Leader Offering Dividend Value and Growth - MSN
Can swing trading help recover from Abbott Laboratories lossesMarket Weekly Review & Target Return Focused Picks - newser.com
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - sharewise.com
Detecting support and resistance levels for Abbott LaboratoriesMarket Activity Recap & Weekly Sector Rotation Insights - newser.com
NZ's Synlait cuts annual loss, inks asset sale deal; shares surge - Reuters
Smith Chas P & Associates PA Cpas Sells 2,167 Shares of Abbott Laboratories $ABT - MarketBeat
GC Wealth Management RIA LLC Grows Position in Abbott Laboratories $ABT - MarketBeat
Klein Pavlis & Peasley Financial Inc. Acquires Shares of 17,000 Abbott Laboratories $ABT - MarketBeat
What to Expect From Abbott Laboratories' Next Quarterly Earnings Report - Yahoo Finance
Moody Lynn & Lieberson LLC Sells 12,285 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Fort Washington Investment Advisors Inc. OH - MarketBeat
Can volume confirm reversal in Abbott Laboratories2025 Fundamental Recap & Real-Time Market Sentiment Alerts - newser.com
China’s Bright Dairy to Sell New Zealand Assets to Abbott for USD170 Million - 一财全球Yicai Global
Synlait Milk reports full-year loss ahead of asset sale - RNZ
Synlait sells Pōkeno site for $307m, manufacturing woes batter bottom line - ThePost.co.nz
Finanzdaten der Abbott Laboratories-Aktie (ABT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.83%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):